Is Mango Medical profitable?

No. As of March 2026 Mango Medical is a pre-revenue Y Combinator W26 startup with 1 to 10 employees. It claims an 8 figure letter of intent from a top orthopedic company, but this is a non binding LOI, not booked revenue, per its own YC profile.

Could AI or incumbents replace Mango Medical?

Yes, structurally. Mango Medical sells API planning services to implant makers who can absorb the capability directly. Zimmer Biomet already bought comparable AI planning startup OrthoGrid Systems in August 2024, showing incumbents are consolidating this exact niche.

Who is Mango Medical's biggest competitor?

Zimmer Biomet is the sharpest threat after acquiring AI surgical planning startup OrthoGrid Systems in August 2024 for a company that had raised about $9.37M. Stryker's Mako platform and smaller AI planner Formus Labs also compete in orthopedic surgical planning.

Who owns Mango Medical?

Mango Medical is privately held and venture backed, part of Y Combinator's Winter 2026 batch. Its legal imprint lists a Delaware parent, Mango Medical Inc, at 1209 Orange Street, Wilmington, with European operations based in Garching bei München, Germany.

Has Mango Medical raised funding?

No primary funding announcement was found. A third party aggregator, extruct.ai, estimated total funding around $8 to $8.3 million as of June 2026, but this figure is unconfirmed by any press release, filing, or named investor.

Does Mango Medical have FDA clearance?

Not yet. As of its March 2026 Y Combinator launch, Mango Medical states it is pursuing FDA 510(k) clearance for its orthopedic surgical planning software, but clearance has not been granted according to its own company profile.

YC Winter 2026 · subsidiary of Mango Medical Inc. (Delaware) · Germany

Mango Medical

YC W26 startup building AI foundation models for planning orthopedic implant surgery.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: FDA 510(k) clearance decision on Mango's planning software

The call

Mango sells planning software to the same implant makers who can build or buy that capability themselves, and one already has.

Mango Medical builds software that helps surgeons plan implant procedures using artificial intelligence. Right now, the company sells its tools directly to the big implant makers like Zimmer Biomet and Stryker, which is risky because these giants have already shown they will buy up competitors (Zimmer bought OrthoGrid in August 2024) or build the technology themselves. The one thing that could save Mango is if it stops selling to individual implant makers and instead sells directly to hospitals and surgeons as a tool that works with any brand, making the big companies unable to compete without creating conflicts with their own sales teams. Without this shift in the next 18 to 24 months, Mango will likely be acquired as a feature rather than survive as its own company.

Why

AI pressure: None apparent. Generic AI models lack surgical imaging data and liability cover, so they feed Mango's approach more than they eat it. Could AI do the core job? Only partly.

Bigger players: Zimmer Biomet (via OrthoGrid acquisition), Stryker Mako, Materialise. Zimmer Biomet already bought an AI planning company in August 2024, and Stryker's Mako platform is live in the same surgeries. Could a giant copy it? Yes, easily.

What protects it. Surgeon-specific training data and pending FDA clearance are hard for a big implant maker to fake overnight.

What would change this call

Mango's 8-figure LOI converts to a signed, binding contract with a named implant maker. Shows real distribution but may lock Mango into a single-vendor captive model.
Mango Medical receives FDA 510(k) clearance for its planning software. Removes regulatory uncertainty and signals product is nearing market use.
Zimmer Biomet, Stryker, or Materialise launch a comparable AI-native planning feature. Would show incumbents closing the gap before Mango secures a durable position.

Key numbers

Zimmer Biomet acquired OrthoGrid Systems (Aug 2024)
Mango has 1 to 10 employees (Jun 2026)
Mango cites an unconfirmed 8-figure LOI (Mar 2026)

Named risks

White-label API sales to a single implant maker invite acqui-hire absorption rather than durable independent business. Severity: high
Zimmer Biomet's August 2024 OrthoGrid acquisition proves incumbents are buying, not licensing, AI planning capability. Severity: high
FDA 510(k) clearance remains pending as of March 2026 with no confirmed grant date. Severity: medium
Core traction claim is a non-binding LOI with no named customer or signed contract disclosed. Severity: medium
No primary source confirms funding amount; only aggregator estimate of $8 to $8.3M exists. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Zimmer Biomet	losing to	Acquired AI surgical planning startup OrthoGrid Systems in August 2024, consolidating the niche
Stryker	contesting	Mako platform cited as AI-enabled orthopedic surgical tech leader as of May 2025
Formus Labs	contesting	AI-automated 3D joint replacement planner, founded 2016, raised $5.75M as of July 2025

Questions people ask

Is Mango Medical profitable?: No. As of March 2026 Mango Medical is a pre-revenue Y Combinator W26 startup with 1 to 10 employees. It claims an 8 figure letter of intent from a top orthopedic company, but this is a non binding LOI, not booked revenue, per its own YC profile.
Could AI or incumbents replace Mango Medical?: Yes, structurally. Mango Medical sells API planning services to implant makers who can absorb the capability directly. Zimmer Biomet already bought comparable AI planning startup OrthoGrid Systems in August 2024, showing incumbents are consolidating this exact niche.
Who is Mango Medical's biggest competitor?: Zimmer Biomet is the sharpest threat after acquiring AI surgical planning startup OrthoGrid Systems in August 2024 for a company that had raised about $9.37M. Stryker's Mako platform and smaller AI planner Formus Labs also compete in orthopedic surgical planning.
Who owns Mango Medical?: Mango Medical is privately held and venture backed, part of Y Combinator's Winter 2026 batch. Its legal imprint lists a Delaware parent, Mango Medical Inc, at 1209 Orange Street, Wilmington, with European operations based in Garching bei München, Germany.
Has Mango Medical raised funding?: No primary funding announcement was found. A third party aggregator, extruct.ai, estimated total funding around $8 to $8.3 million as of June 2026, but this figure is unconfirmed by any press release, filing, or named investor.
Does Mango Medical have FDA clearance?: Not yet. As of its March 2026 Y Combinator launch, Mango Medical states it is pursuing FDA 510(k) clearance for its orthopedic surgical planning software, but clearance has not been granted according to its own company profile.

Timeline

2026-06-07Startuphub.ai restates Mango Medical's LOI as a '$10M ARR' claim
2026-03-31CB Insights profile confirms Zimmer Biomet's OrthoGrid acquisition data
2026-03-11Mango Medical publicly launches via Y Combinator's Launch YC post
2025-07-04CB Insights lists Formus Labs total raised at $5.75M
2024-08Zimmer Biomet acquires AI surgical planning startup OrthoGrid Systems
2024Mango Medical founded, per extruct.ai aggregator listing
2016Competitor Formus Labs founded in Auckland, New Zealand

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company